Event Gaps: Perplexity's picks for 2026-10-08
Perplexity picked PEP, DAL, STZ, PFE, BMY for a 1-day horizon. Intraday alpha vs SPY: -0.44%. Picks with positive alpha: 40%.
| Experiment | Event Gaps |
|---|---|
| Model | Perplexity |
| Prompt version | event-gap-v12 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-08 |
| Measured to | 2026-10-09 |
| Benchmark | SPY |
| Status | Settled |
| Intraday alpha vs SPY | -0.44% |
| Picks with positive alpha | 40% |
| Benchmark return | +0.06% |
The picks
| Rank | Symbol | Gap direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | PEP | -0.38% | +0.38% | 72% | +0.32% | Yes | |
| 2 | DAL | -1.84% | +1.84% | 68% | +1.77% | Yes | |
| 3 | STZ | +1.56% | -1.56% | 65% | -1.63% | No | |
| 4 | PFE | +1.36% | -1.36% | 70% | -1.42% | No | |
| 5 | BMY | +1.17% | -1.17% | 60% | -1.24% | No |
The model's market view
U.S. equities are pulling back from record highs as Treasury yields climb to multi-year peaks, reviving inflation concerns. The S&P 500 and Nasdaq retreated Wednesday after setting intraday and closing records, with the 10-year yield touching its highest level since 2002. Earnings season is underway with mixed reactions: companies beating estimates but guiding conservatively are being punished, while FDA approvals in biopharma are providing single-stock catalysts. The market is searching for direction as tech rebounds square off against rising yields, higher oil prices, and AI valuation concerns.
Why each pick
PEP
PepsiCo reported Q3 2026 earnings before the open on October 8, beating EPS ($2.34 vs. $2.29) and revenue ($25.27B vs. $24.95B), but cut full-year core EPS growth guidance to 2.5%-3.5% from 5%-7% low end, citing weak North American snack demand and margin pressure. The stock fell 1.58% to $123.73 on October 7 and traded near $124.28 intraday on October 8. The guidance cut overshadows the quarterly beat, and analyst downgrades have piled on. However, the initial selloff may be overdone given the revenue beat and international strength. Emotional continuation risk: shares are near 52-week lows and could see further pressure if investors focus on the North American weakness, but a short-term bounce is possible as the guidance cut was already partially anticipated. Thesis: stock drifts lower into the close as guidance concerns dominate. Risks: defensive rotation or short-covering could limit downside.
DAL
Delta Air Lines is scheduled to report Q3 2026 earnings before the open on Friday, October 9, 2026. Management guided the September quarter to mid-teens revenue growth, 11%-13% operating margin, and EPS of $2.00-$2.50. The stock closed at $82.97 on October 7, down 0.82%, and traded at $82.00 in pre-market on October 8. Analysts are focused on whether premium demand and Amex remuneration can offset rising fuel costs (June quarter fuel was $3.93/gallon, up 75% YoY; September guide assumes ~$3.15). The stock is below its 52-week high of $95.68. Thesis: ahead of earnings, uncertainty around fuel costs and the high bar for Q4 guidance could weigh on the stock, leading to a modest decline. Emotional continuation risk: the stock has been resilient YTD (+20%) but faces a reality check if fuel concerns dominate. Risks: positive premium travel data or raised guidance could spark a rally.
STZ
Constellation Brands reported Q2 FY2027 earnings after the close on October 6, 2026, beating EPS ($3.74 vs. $3.55) and revenue ($2.63B vs. $2.54B), but reiterated FY2027 EPS guidance of $11.20-$11.90, below the ~$11.74 consensus midpoint. The stock initially fell 4%+ after hours, then rebounded 2.35% to $118.39 on October 7, and traded at $116.46 on October 8. Beer depletions were -0.6% (below +0.1% consensus), though management cited September improvement. Thesis: the stock faces emotional continuation risk as investors remain concerned about Modelo momentum and margin pressure. The guidance reiteration (not raise) despite the beat is a negative signal. The stock could drift lower as the market digests the durable demand concerns. Risks: short-covering or positive scanner data could spark a rebound.
PFE
Pfizer announced on October 7-8, 2026 that the FDA approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab for maintenance treatment of adults with unresectable, locally advanced, or metastatic HER2+ breast cancer after induction treatment. This expands TUKYSA into the front-line setting. The stock closed at $28.00 on October 7, up 1.82%, on heavy volume (31.2M shares vs. 36M avg). Market cap is ~$159.6B. Thesis: the FDA approval is a positive catalyst that could drive continued momentum, but the stock has underperformed YTD (+12% vs. S&P +14%) and faces overhang from patent expirations (Eliquis, Opdivo 2028). The approval may already be partially priced in given the 1.8% pop on October 7. Emotional continuation risk: the stock could see a modest pullback as traders take profits after the initial pop. Risks: further positive analyst commentary or raised price targets could extend gains.
BMY
Bristol-Myers Squibb received FDA approval on September 30, 2026 to expand CAMZYOS (mavacamten) to adults and pediatric patients (weighing 30 kg or more) with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The stock closed at $59.70 on October 7, up 0.18%, with avg volume ~11.2M shares. Market cap is ~$122B. Thesis: the label expansion is a positive catalyst, but the stock has already rallied significantly YTD (+15.6% vs. S&P +14%) and faces overhang from Eliquis/Opdivo patent expirations in 2028. The approval was announced on September 30, so some of the positive reaction may have already occurred. Emotional continuation risk: the stock could see modest profit-taking after the recent run-up. Risks: positive analyst commentary on the commercial opportunity or raised price targets could extend gains.
Other models on the same run
| Model | Picks | Intraday alpha vs SPY | Picks with positive alpha |
|---|---|---|---|
| GPT-6 | APLD, LEVI, DAL, STZ, PEP | +0.94% | 80% |
| Muse Spark 1.1 | PEP, TSM, DAL, LEVI, STZ | -1.66% | 20% |
| Gemini 1.5 Pro | SPOT, PEP, CW, MRNA, DAL | +1.66% | 80% |
| Grok 4 | ARGX, PENG, PEP, DAL, STZ | -0.09% | 40% |
| Claude Sonnet 5.5 | DAL, APLD, WOLF, PEP, LEVI | +0.42% | 60% |
| DeepSeek | DAL, HUM, SPCX, UNH, WOLF | +3.12% | 80% |
Written up on ForecastNest Insights: Event Gaps: Perplexity's picks for 2026-10-08.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.